Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. ...

Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized

Related Keywords

Denmark ,United States ,Thomash Jensen ,Mike Beyer ,Eli Lilly ,Jeremyr Graff ,Jamesg Cullem ,Thomas Pedersen ,Jerry Mclaughlin ,Johns Hopkins University School Of Medicine ,Linkedin ,Smerud Medical Research International ,Nasdaq ,Carrotize Pr Communications ,Exchange Commission ,Company Contact ,Sam Brown Inc ,Allarity Therapeutics Inc ,Scientific Advisory Board Of Avicenna Biosciences Inc ,Allarity Therapeutics ,Interim Chief Executive ,Executive Advisor ,Wood Hudson Cancer Research Laboratory ,Scientific Advisory Board ,Avicenna Biosciences ,Johns Hopkins University School ,Drug Response Predictor ,Companion Diagnostic ,Looking Statements ,Private Securities Litigation Reform Act ,Nasdaq Listing ,Business ,